tradingkey.logo
tradingkey.logo

LTZ Therapeutics Announces Strategic Collaboration With Eli Lilly To Advance Development Of Its Myeloid Engager Platform For Autoimmune Diseases

ReutersJul 29, 2025 2:17 PM

- Eli Lilly and Co LLY.N:

  • LTZ THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH ELI LILLY TO ADVANCE DEVELOPMENT OF ITS MYELOID ENGAGER PLATFORM FOR AUTOIMMUNE DISEASES

  • LTZ THERAPEUTICS: UNDER TERMS OF AGREEMENT, LTZ WILL RECEIVE A DOUBLE-DIGIT MILLION USD UPFRONT PAYMENT AND AN EQUITY INVESTMENT IN COMPANY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI